15 abstracts covering advances in early recurrence detection, tumor profiling, and treatment response monitoring

Guardant Health, Inc, a leading precision oncology company, announced that new data from its oncology portfolio will be presented in 15 accepted abstracts at the European Society for Medical Oncology (ESMO) 2025 Congress, taking place October 17-21 in Berlin, Germany. These presentations span the cancer care continuum, from minimal residual disease (MRD) detection and recurrence monitoring to late-stage tumor profiling and treatment response assessment.

Health Technology Insights: RIS Rx Appoints John Driscoll as Chairman of the Board

Guardant Health’s accepted abstracts cover multiple tumor types, including lung, colorectal, breast, head and neck, and cancers of unknown primary. Together, they underscore the company’s commitment to leveraging cutting-edge genomic and epigenomic knowledge to improve patient outcomes at all stages of the disease.

“We are proud that Guardant’s innovative technologies and research collaborations are highlighted in several abstracts presented at ESMO this year,” said Craig Eagle, Chief Medical Officer of Guardant Health. “These studies highlight how our technologies are helping to advance precision oncology, from earlier detection of recurrences, to guiding optimal treatment choices, to monitoring treatment effectiveness across a wide range of cancers.”

Health Technology Insights: First Care Clinic Boosts Efficiency with eClinicalWorks and Sunoh.ai

Key points:

  • New applications of Guardant Infinity in tumor profiling : Data from the SIBYL study highlight the ability of molecular lung subtyping to refine histological characterization and associated decision-making in non-small cell lung cancer, while results from the CUPIDO study highlight the utility of molecular tumor typing to provide information on cancers of unknown primary, thus addressing a major unmet clinical need.
  • Therapeutic monitoring in advanced cancers : Updated results from the CROWN study demonstrate how Guardant Reveal can monitor treatment response in anaplastic lymphoma kinase-positive (ALK+) lung cancer, using ctDNA analysis to better understand patients’ response to treatment.
  • Advances in MRD Detection and Recurrence Monitoring : Results from the PEGASUS, PRECISION, and Decision Impact colorectal cancer studies, along with new head and neck cancer data from two independent studies, demonstrate the performance and utility of Guardant Reveal™ in early recurrence detection and guiding treatment decisions.
  • New data on fibroblast growth factor receptor (FGFR) alterations as an emerging biomarker in non-small cell lung cancer (NSCLC), comparing Guardant360 Liquid detection rates with known tissue datasets.

Health Technology Insights: Flatiron Health Advances Real-World Evidence with Predictive Insights

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com

Source – businesswire